Tartary Buckwheat Flavonoids Improve Colon Lesions and Modulate Gut Microbiota Composition in Diabetic Mice.
Level 5 - mechanism / opinion, no new human data
Animal research without human clinical data
PubMed 36016679 · doi:10.1155/2022/4524444
What was done
Investigated the effects of Tartary buckwheat flavonoids (TBFs) on metabolic parameters, systemic inflammation, colon histopathology, and gut microbiota composition in a diabetic mouse model.
What was found
The authors reported that TBFs reversed blood glucose levels and body weight changes, improved lipid parameters (total cholesterol, triglycerides, LDL-C, HDL-C), reduced inflammatory markers (TNF-α, IL-6), improved fasting insulin, and attenuated diabetes-related colon lesions. TBF treatment was also associated with increases in taxa such as Akkermansia, Prevotella, Roseburia, and Odoribacter, alongside decreases in Escherichia, Mucispirillum, and Bilophila. The abstract reports no numerical values, effect sizes, or confidence intervals.
Why it matters
Provides preclinical evidence that Tartary buckwheat flavonoids may modulate gut microbial composition in ways correlated with improved glycemic, lipid, and colonic outcomes in experimental diabetes.
Limits
This is an animal study, limiting applicability to human metabolic disease. The abstract does not report sample size, dosage, intervention duration, or quantitative data.
Cited by
- supports The polyphenols and fiber in Himalayan tartary buckwheat modulate the microbiome in ways that assist blood sugar control.